BioAlliance Pharma announces the grant of its European acyclovir Lauriad patent
BioAlliance Pharma SA announced the grant of a European patent protecting its product acyclovir Lauriad®. This patent is now validated in all European countries; this first patent validation is a major step and the procedures up to the grant are ongoing in the other major global areas, America and Asia. This patent specifically protects the muco-adhesive tablet containing acyclovir, its process for manufacturing and its clinical application.
«Acyclovir Lauriad® enables a treatment of recurrent herpes labialis on the basis of one tablet application as soon as the first signs of infection appear. We are now looking for the adequate commercial partner for this innovation in the herpes labialis market. The agreement of the European and US Health Authorities, obtained this summer, to plan a registration dossier submission in 2011, together with the progress of our patents are obviously key steps in this process», stated Dominique Costantini, CEO of BioAlliance Pharma.
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.